EU Approvals: Evenity Cleared For Severe Osteoporosis
Contraindicated In Patients With MI, Stroke History
The European Commission has granted a marketing authorization for UCB and Amgen’s bone-building MAb, romosozumab, and first launches are expected in the first half of 2020; patient groups suggest that the prevention and treatment of fragility fractures has not attracted the attention it deserves.
